Valacyclovir in the treatment of genital herpes and herpes zoster

REFERENCES

• HAYDEN RG: Antimicrobial agents. In: Goodman & Gilman's The Pharmacological Bash of Therapeutics. Hardman JG, Limbird LE (Eds.), McGraw-Hill, New York, USA (1996):1191–1223.
   Google Scholar
• DRAKE S, TAYLOR S, BROWN D PILLAY D: Improving the care of patients with genital herpes. Br Med. 1 (2000) 321:619–623.
   PubMed Web of Science ®Google Scholar
• STEIN GE: Pharmacology of new antiherpes agents: famciclovir and valacyclovir. 1. Am. Pharm. Assoc. (1997) S37:157–163.
   Google Scholar
• LITTLER E: Safety and efficacy issues of herpesvirus drugs. Antiviral Chem. Chemother (1994) 5\(Suppl. 1):11–16.
   Google Scholar
• LUBER AD, FLAHERTY JF: Famciclovir for treatment of herpesvirus infections. Ann. Pharmacother. (1996) 30:978–985.
   PubMed Web of Science ®Google Scholar
• ORMROD D, SCOTT LJ, PERRY CM: Valaciclovir: a review of its long-term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs (2000) 59:839–863.
   PubMed Web of Science ®Google Scholar
• FIFE KH, BARBARASH RA, RUDOLPH T, DEGREORIO B, ROTH R: Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Sex. Tramm. Dis. (1997) 24:481–486.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, TYRING SK, DEGREGORIO B, MILLER C, BEUTNER K: A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med. (1996) 156:1729-1735.•Pivotal placebo-controlled trial of oral valacyclovir for episodic treatment of recurrent genital herpes.
   Google Scholar
• TYRING SK, DOUGLAS JM, COREY LSPRUANCE SL, ESMANN J: A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch. Dermatol (1998) 134:185–191.
   PubMedGoogle Scholar
• BODSWORTH NJ, CROOKS RJ, BORELLI S et al.: Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double-blind clinical trial. Geriitounn. Med. (1997) 73:110–116.
   Google Scholar
• SAIAG P, CHASTANG C, BERTIN I et al.: Efficacy, safety and equivalence of 1000 mg once daily and 500 mg twice daily valaciclovir in recurrent genital herpes. Program and Abstracts of the 38th ICAAC San Diego CA, USA (15–18 September 1996). Abstract H–113.
   Google Scholar
• LEONE PA, TROTTIER S, MILLER JMet al: A comparison of oral valaciclovir 500 mg twice daily for three or five days in the treatment of recurrent genital herpes. Program and Abstracts of the 8th International Congress of Infectious Disease. Boston MA, USA (15 –18 May 1998). Poster 22.012: 90.
   Google Scholar
• REITANO M, TYRING S, LANG W et al.: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study. j Infect. Dis. (1998) 178:603–610.
   PubMed Web of Science ®Google Scholar
• BAKER DA, BLYTHE JG, MILLER JM: Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obstet. Gyrrecol. (1999) 94:103-106. •Pivotal trial demonstrating efficacy of once-daily valacyclovir for the suppression of recurrent genital herpes infection.
   Google Scholar
• DRUCKER JL, MILLER JM, THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Once-daily valaciclovir sustains the suppressive efficacy and safety record of acyclovir recurrent genital herpes. 1st European Congress of Chemotherapy Scotland, UK (14 –19 May 1996). Abstract.
   Google Scholar
• LAWRENCE AG, BELL AR, THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Valaciclovir for prevention of recurrent herpes simplex virus infection in HIV-infected individuals — a double-blind controlled trial. 8th European Congress of Clinical Microbiology and Infectious Disease. Lausanne, Switzerland (25 –28 May 1997).
   Google Scholar
• MERTZ GJ, BENEDETTI J, ASHLEY R SELKE SA, COREY L: Risk factors for the sexual transmission of genital herpes. Ann. Intern. Med. (1992) 116:197–202.
   PubMed Web of Science ®Google Scholar
• WALD A, WARREN T, HUH et al.: Suppression of subclinical shedding of herpes simplex virus Type 2 in the genital tract with valacyclovir. Programs and Abstracts of the 38th ICAAC San Diego CA, USA (24 — 27 September 1998). Abstract H–82.
   Google Scholar
• BEUTNER KR, FRIEDMAN DJ, FORSZPANIAK C ANDERSEN PL, WOOD MJ: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother (1995) 39:1546–1553.
   PubMed Web of Science ®Google Scholar
• TYRING SK, BEUTNER KR, TUCKER BA et al.: Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch. Fam. Med. (2000) 9:863-869. •Head-to-head comparator trial showing comparable efficacy of valacyclovir and famciclovir in the treatment of herpes zoster.
   Google Scholar
• FIFE KG, CRUMPACKER CS, MERTZ GJ, HILL EL, BOONE GS: Recurrence and resistance patterns of herpes simplex virus following cessation of at least 6 years of chronic suppression with acyclovir. Infect. Dis. (1994) 169:1338–1341.
   Google Scholar
• FEINBERG JE, HURWITZ S, COOPERD et al.: A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. I Infect. Dis. (1998)
   Google Scholar